# Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy

> **NCT06393465** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 50 (actual)

## Conditions studied

- Transthyretin Amyloidosis Cardiomyopathy (ATTR-CM)

## Interventions

- **DRUG:** Tafamidis

## Key facts

- **NCT ID:** NCT06393465
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2024-06-15
- **Primary completion:** 2026-04-07
- **Final completion:** 2026-04-07
- **Target enrollment:** 50 (ACTUAL)
- **Last updated:** 2026-04-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06393465

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06393465, "Real-World Effectiveness of High-Dose Tafamidis on Neurologic Disease Progression in Mixed-Phenotype Transthyretin Amyloid Cardiomyopathy". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT06393465. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*